Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12321635 | PMC |
| http://dx.doi.org/10.1016/j.tjpad.2025.100213 | DOI Listing |
Publication Analysis
Top Keywords
erratum "intercept-ad
4
"intercept-ad phase
4
phase study
4
study intravenous
4
intravenous sabirnetug
4
sabirnetug participants
4
participants mild
4
mild cognitive
4
cognitive impairment
4
impairment mild
4
Similar Publications
Erratum to "INTERCEPT-AD, a phase 1 study of intravenous sabirnetug in participants with mild cognitive impairment or mild dementia due to Alzheimer's disease" [J Prev Alzheimers Dis 2025;12(1): 100005.].
J Prev Alzheimers Dis
August 2025
CenExel iResearch, Atlanta, GA, USA.
Erratum to "Biofluid biomarker changes following treatment with sabirnetug (ACU193) in INTERCEPT-AD, a phase 1 trial in early Alzheimer's disease" [J Prev Alzheimers Dis 2025;12(4): 100082].
J Prev Alzheimers Dis
August 2025
Acumen Pharmaceuticals, Inc, 1210-1220 Washington St., Suite 210, Newton, MA 02465, USA.